Zhejiang Tailin BioEngineering Co (300813) Fair Value & Analysis
Healthcare · CN · Market cap 2.4B CNY
Fair value as of: Jul 9, 2026
From 23 valuation models · updated 32 days ago
Share price −5.7% over the past month.
Below-average quality, and screening another 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.08). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (¥1.47 to ¥3.08) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥12.02 – ¥63.84 · fair‑value band ¥1.47 – ¥3.08 · the ¥20.75 price screens above the ¥2.14 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Zhejiang Tailin BioEngineering Co (300813) currently trades at ¥20.75, while our model-based Fair Value estimate is ¥2.14, implying the stock looks roughly 89.7% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhejiang Tailin BioEngineering Co generated revenue of 340M CNY at a net margin of 4.9%. Revenue grew 18.6% year over year. It earns a return on equity of 2.0%. The balance sheet holds a net cash position of 149M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥1.47 (bear case) to ¥3.08 (bull case); at ¥20.75, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 51% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -90%, 300813 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Economic Profit (¥4.46) versus Growth DCF (¥0.4500). Highest evidence: Growth DCF (80).
Notify me when 300813 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally.
Full company description
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. It also provides pharma processing, such as pharma isolators, high-precision filling and dispensing, sterile transfer; cell and gene therapy; radiopharma; laboratory animal; leak test systems; biodecontamination, including VH2O2 sterilization system and dry fogging system; sterilization monitoring and validation; microbiological testing, comprising sterility and microbial limit test system and pretreatment instruments; and water quality, consisting of microbial monitoring and aquatic organism detection system, total organic carbon (TOC) analysis, enzyme substrate method, and automatic detection system for cryptosporidium and giardia. In addition, the company offers filtration membranes, such as flat and blotting membranes, IVD series, membrane filters and dispensers; and analytical instruments, including filter integrity testing, container closure integrity testers (CCIT), water activity meters, and biodegradation analysis systems. Its products are used in biopharmaceuticals, medical and health care, laboratory animal research, food safety, disease control, water quality monitoring, and environmental protection. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. Zhejiang Tailin BioEngineering Co.,Ltd was founded in 1993 and is based in Hangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Tailin BioEngineering Co reported revenue of ¥334M in FY2025 versus ¥283M in FY2021, a compound +4.2%/yr. Reported net income was ¥16.5M in FY2025, compounding −28.6%/yr from FY2021.
of which total revenue +15.9 pp · buybacks/dilution −11.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
300813 screens 90% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Zhejiang Tailin BioEngineering Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang Tailin BioEngineering Co (300813) overvalued or undervalued?
What is the fair value of 300813?
What is the quality score of 300813?
What is the revenue of Zhejiang Tailin BioEngineering Co (300813)?
What is the net profit margin of 300813?
Does Zhejiang Tailin BioEngineering Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Tailin BioEngineering Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.